Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Olumacostat Glasaretil

Olumacostat Glasaretil
Contact us for more batch information
Select Batch
Resource Download

Olumacostat Glasaretil

Catalog No. T3510Cas No. 1261491-89-7
Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC). It has been used in trials studying the treatment of Acne Vulgaris.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$50In Stock
2 mg$61In Stock
5 mg$97In Stock
10 mg$147In Stock
25 mg$279In Stock
50 mg$478In Stock
100 mg$697In Stock
200 mg$992In Stock
1 mL x 10 mM (in DMSO)$98In Stock
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "Olumacostat Glasaretil"

Product Introduction

Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC). It has been used in trials studying the treatment of Acne Vulgaris.
In vitro
Acetyl coenzyme A carboxylase plays a pivotal role in regulating the initial, critical step of fatty acid biosynthesis. Olumacostat glasaretil effectively impedes de novo lipid formation in both primary and transformed human sebocytes, significantly diminishing fatty acid synthesis to equal or lower than baseline levels at a concentration of 3 μM. Moreover, cultures of SEB-1 cells exhibit a marked reduction, between 85% to 90%, in ^14C-acetate incorporation when treated with 20 μM of olumacostat glasaretil, relative to untreated controls. At a lower dose of 3 μM, olumacostat glasaretil notably decreases the accumulation of several lipids in sebocytes, including triacylglycerol, cholesteryl/wax ester, diacylglycerol, cholesterol, and phospholipids by approximately 86%, 57%, 51%, 39%, and 37%, respectively[1].
In vivo
Olumacostat glasaretil, a pro-drug of the ACC inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA), is designed for improved in vivo delivery. Unlike TOFA, topical application of olumacostat glasaretil notably decreases the size of sebaceous glands in hamster ears. HPLC analysis of hamster ear extracts indicates that treatment with olumacostat glasaretil raises ACC levels and increases the acetyl-CoA to free CoA ratio in subjects, suggesting enhanced fatty acid oxidation linked to ACC inhibition. Furthermore, MALDI imaging demonstrates that olumacostat glasaretil, when applied to Yorkshire pig ears, predominantly accumulates in sebaceous glands compared to the adjacent dermis. After 12 weeks, olumacostat glasaretil treatment results in significant decreases in both inflammatory and noninflammatory lesions, with a higher percentage of patients achieving at least a 2-grade improvement in investigator global assessment score compared to those treated with a placebo vehicle.
Cell Research
Primary human sebocytes are grown to confluence in 96-well plates in sebocyte growth medium and stimulated with 1 μM human insulin and 1 μM liver X receptor (LXR) agonist T0901317 in the presence of increasing concentrations of TOFA or olumacostat glasaretil in culture medium containing 0.1% DMSO. After 24 hours, stimulation/treatment medium is removed and test articles are reapplied in labeling medium containing [14C]-acetate. Following an additional 16 hours, cells are harvested using trypsin/EDTA. Lipid extracts are prepared and the amount of [14C]-acetate incorporation is determined by liquid scintillation as a measure of de novo fatty acid synthesis[1].
Chemical Properties
Molecular Weight481.62
Cas No.1261491-89-7
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
H2O: < 0.1 mg/mL (insoluble)
DMSO: 125 mg/mL (259.54 mM)
Solution Preparation Table
1 mM2.0763 mL10.3816 mL20.7633 mL103.8163 mL
5 mM0.4153 mL2.0763 mL4.1527 mL20.7633 mL
10 mM0.2076 mL1.0382 mL2.0763 mL10.3816 mL
20 mM0.1038 mL0.5191 mL1.0382 mL5.1908 mL
50 mM0.0415 mL0.2076 mL0.4153 mL2.0763 mL
100 mM0.0208 mL0.1038 mL0.2076 mL1.0382 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc